Expanding targeted immune modulators in ulcerative colitis

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

(2021) Brian G Feagan et al.   LANCET

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

(2020) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

(2020) Pablo Olivera et al.   GASTROENTEROLOGY

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis

(2020) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis

(2020) Siddharth Singh et al.   GASTROENTEROLOGY

Small molecule oral targeted therapies in ulcerative colitis

(2020) Uday N Shivaji et al.   Lancet Gastroenterology & Hepatology

Filgotinib: First Approval

(2020) Sohita Dhillon et al.   DRUGS

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis

(2018) Stephen Hanauer et al.   Clinical Gastroenterology and Hepatology